Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Conference report highlights new research into drug delivery to treat eye disease: Group explores alternatives to surgery and intravitreous injection

Abstract:
Researchers are investigating microneedles, nanoparticles and polymer carriers as potential new techniques to combat the leading cause of visual impairment and blindness in the United States, according to a report from the Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.

Conference report highlights new research into drug delivery to treat eye disease: Group explores alternatives to surgery and intravitreous injection

Rockville, MD | Posted on November 18th, 2008

The report (www.iovs.org/cgi/content/full/49/11/4712) includes summaries from seven sessions on techniques for ocular drug delivery to the posterior segment of the eye and includes the findings of and opinions of more than 30 top ophthalmic researchers, brought together by the ARVO Foundation for Eye Research. The article in the November issue of Investigative Opthalmology & Visual Science defines the current research and the future needs for ocular drug delivery.

Diseases of the posterior segment of the eye are responsible for the majority of visual impairment and blindness cases in the United States, according to George Williams, MD. Until recently, these diseases were primarily treated with surgery, but recent developments in drug therapies have either replaced or complemented surgery.

But the challenge lies in delivering the drugs. Topical delivery such as ointments and drops are fairly ineffective, and delivery via intravitreous injection (an injection into the fluid in the behind the lens in the eye) can be hard on the patient. According to the report, "Improved drug delivery technologies that provide optimal pharmacokinetics, dose intervals and less invasive routes of administration are needed."

During the two-day event, John Heckenlively, MD, joined Jayakrishna Ambarti, MD, in a session on animal models of posterior ocular diseases. Allan Hoffman, ScD, discussed the design of polymer carriers for intracellular delivery of biomolecular drugs, such as peptides, proteins and nucleic acid drugs. His group is focused on using a family of acid-sensitive polymers to help deliver one of the latest drugs, silencing RNA (siRNA).

Another group of presenters discussed the use of nanoparticles, microbeads and microneedles. Mansoor M. Amiji, PhD, said that nanoparticles can help overcome barriers to drug delivery from the organ level to the subcellular level. Another research laboratory was investigating the effectiveness of hollow and solid microneedles that penetrate only hundreds of micrometers into the cornea or sclera to deliver drugs.

A safer alternative to direct intravitreous injections might be transscleral delivery into the vitreous using subconjunctival injections, said Michael Robinson, MD, adding that researchers needed a clear understanding of the dynamic barriers for the technique to work in treating retinal diseases. Another researcher in this area, Dayle H. Geroski, PhD, suggested that the relatively high permeability of the sclera offers great potential for transscleral drug delivery, especially for administration to the posterior part of the eye.

Other research focused on photodynamic therapy, which uses a photosensitizer agent that localizes more or less selectively to the target tissue and is activated by light, triggering chemical reactions that injure the target tissue.

Drug Delivery to Posterior Intraocular Tissues:
Third Annual ARVO/Pfizer Ophthalmics Research
Institute Conference
May 4-5, 2007, Fort Lauderdale, Florida
Session I: Unmet Needs and New Drug Opportunities in Treating Disorders of the Posterior Segment
Session II: Animal Models of Posterior Ocular Diseases
Session III: New Drug Design and Delivery Systems: What Do Experts See Beyond the Horizon?
Session IV: Ocular Drug Delivery Using Nanoparticles, Microbeads and Microneedles
Session V: Transscleral, Intravitreous and Suprachoroidal Drug Delivery
Session VI: Ocular Tissue Dissection, Modeling, and Ocular Tissue Assays
Session VII: Iontophoresis, Electroporation, Electrophoresis and Photo-acoustic Delivery

Henry F. Edelhauser, Jeffrey H. Boatright, John M. Nickerson and the Third ARVO/Pfizer Research Institute Working Group. Drug Delivery to Posterior Intraocular Tissues: Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. Invest. Ophthalmol. Vis. Sci. 2008;49: 4712-4720.

####

About Association for Research in Vision and Ophthalmology
ARVO is the largest eye and vision research organization in the world. Members include more than 12,500 eye and vision researchers from over 70 countries. The Association encourages and assists research, training, publication and dissemination of knowledge in vision and ophthalmology. The ARVO Foundation for Eye Research exists to provide continuing education and stable support for original and innovative vision research, particularly research with translational impact that fosters collaboration between clinicians and basic scientists. The Foundation also supports training for new vision research scientists around the world.

For more information, please click here

Contacts:
Jo Olson

240-221-2923

Copyright © Association for Research in Vision and Ophthalmology

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New exotic phenomena seen in photonic crystals: Researchers observe, for the first time, topological effects unique to an “open” system January 12th, 2018

'Decorated' stem cells could offer targeted heart repair January 11th, 2018

Nanotube fibers in a jiffy: Rice University lab makes short nanotube samples by hand to dramatically cut production time January 11th, 2018

IBM Breaks Records to Top U.S. Patent List for 25th Consecutive Year: IBM Inventors Receive Record 9,043 Patents in 2017 in Areas such as Artificial Intelligence, Cloud, Blockchain, Cybersecurity and Quantum Computing January 11th, 2018

Nanomedicine

'Decorated' stem cells could offer targeted heart repair January 11th, 2018

Rice University lab modifies nanoscale virus to deliver peptide drugs to cells, tissues January 8th, 2018

SNUH team develops new nanomaterial for thermal cancer therapy January 5th, 2018

Novel nanomedicine inhibits progression of pancreatic cancer in mice: Survival rates in pancreatic cancer linked to inverse correlation between specific oncogene and tumor suppressant, Tel Aviv University researchers say January 3rd, 2018

Announcements

New exotic phenomena seen in photonic crystals: Researchers observe, for the first time, topological effects unique to an “open” system January 12th, 2018

'Decorated' stem cells could offer targeted heart repair January 11th, 2018

Nanotube fibers in a jiffy: Rice University lab makes short nanotube samples by hand to dramatically cut production time January 11th, 2018

IBM Breaks Records to Top U.S. Patent List for 25th Consecutive Year: IBM Inventors Receive Record 9,043 Patents in 2017 in Areas such as Artificial Intelligence, Cloud, Blockchain, Cybersecurity and Quantum Computing January 11th, 2018

Events/Classes

21st International Conference on Advanced Nanoscience and Nanotechnology December 31st, 2017

Leti Will Demonstrate First 3D Anti-Crash Solution for Embedding in Drones: Fitted on a Mass-Market Microcontroller, 360Fusion Software Technology Detects any Dynamic Obstacle and Helps Guide Drones Away from Collisions December 15th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project